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Key points
C Chronic gastro-oesophageal acid and bile reflux can lead to
Barrett’s oesophagus, a well-described precursor of oesopha-
geal adenocarcinoma
C The incidence of oesophageal adenocarcinoma has been
dramatically increasing in developed countries




Rebecca C FitzgeraldC Regular endoscopic monitoring of Barrett’s oesophagus is
recommended to detect neoplastic changes at an early cura-Abstract
tive stage
C Endoscopic diagnostic and therapeutic technologies to detect
and treat early lesions are rapidly advancing
C Surgery, increasingly combined with chemotherapy and
radiotherapy, remains the main treatment modality for locally
advanced oesophageal adenocarcinoma
C Emerging molecular targeted therapies, such as HER2 and
VEGR inhibitors, can provide additional treatment avenues for
oesophageal adenocarcinoma, and a number of combination
small molecules and immunotherapy treatments are under
evaluationOesophageal adenocarcinoma (OAC) has increased dramatically in
Western countries, including theUK, over thepast 30years. It usually pre-
sentsdenovo, but is oftenprecededbyBarrett’soesophagus (BO), a pre-
malignant condition whereby the normal squamous epithelium is
replaced by columnar lined epithelium with intestinal metaplasia. The
main risk factors for BO include male sex, obesity and chronic gastro-
oesophageal reflux of acid and bile. The estimated annual risk of BO pro-
gression is 0.3%, increasing substantially, up to 30%, when dysplasia is
present. Endoscopic surveillance is recommended to detect neoplastic
changes at an early stage and considerable evidence supports endo-
scopic treatment for confirmed low- and high-grade dysplasia, and intra-
mucosal adenocarcinoma. Most OACs are diagnosed at a more
advanced stage requiring CT-PET assessment and multi-modal treat-
ment. Surgical treatment is performed in specialist centres, increasingly
combined with cytotoxic chemotherapy and radiotherapy, involving
close liaison between members of the multidisciplinary team. Molecular
targeted therapies, such as HER2 and VEGFR-inhibitors, are beginning
to penetrate clinical practice, but high molecular heterogeneity has
impeded progress. In view of the overall dismal survival (<20%) for
advanced OAC, there is renewed interest in screening techniques for
early detection and intervention of dysplastic BO.
Keywords Ablation; adenocarcinoma; Barrett’s oesophagus; bio-
markers; dysphagia; endoscopic mucosal resection; endoscopy;
MRCP; oesophagectomy; radiofrequency; screening; staging;
surveillanceBarrett’s oesophagus
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10.1016/j.mpmed.2019.02.005endoscopically visible segment (1 cm) of metaplastic columnar
epithelium that replaces the normal stratified squamous lining of
the distal oesophagus (Figure 1). BO segments are measured
from columnar mucosa extending proximally from the upper
limit of the gastric folds, which is an anatomical landmark of the
gastro-oesophageal junction (GOJ). Long-standing bile and acid
reflux from the stomach promotes the development of BO, which
in some individuals progresses to adenocarcinoma, via low- and
high-grade dysplasia (LGD and HGD).Epidemiology
The prevalence of BO is difficult to establish, as most patients are
asymptomatic and therefore undiagnosed. Nevertheless, the
estimated prevalence of BO is 1e5% in developed countries.
Gastro-oesophageal reflux disease (GORD), particularly of pro-
longed duration, is the main risk factor. It is more common in
white patients than Hispanic and black individuals. Its preva-
lence increases with age, particularly after 50 years old, until the
70s when it reaches a plateau. The incidence of BO differs
significantly between the sexes, being 2e4 times higher in men
across all age groups.
Obesity is another well-established risk factor, although the
causal relationship between obesity, GORD and BO is not clear.
As well as having mechanical effects on reflux, obesity may
contribute to metaplastic oesophageal conversion by the release
of adipokines. In relation to obesity, some studies indicate that
waist-to-hip ratio is a better predictor of BO than increased body
mass index. There is no evidence that alcohol consumption in-
creases risk of BO, and smoking is thought to be only a moderate 2019 Published by Elsevier Ltd.
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Figure 1 Endoscopic appearance of BO. The transition between the
pale pink squamous oesophagus and the darker columnar metaplasia
that has replaced it in the lower oesophagus can easily be detected
endoscopically.
Risk factors for BO and their association
Factor Relative strength of association








Helicobacter pylori infection Inverse
Table 1
MOUTH AND OESOPHAGUSrisk factor. The risk of progression to HGD and cancer is, how-
ever, significantly increased in smokers with BO.
There appears to be familial clustering in approximately 7%
of BO cases, suggesting a genetic predisposition. Although
monogenic mutations responsible for familial BO and adeno-
carcinoma have not been identified, recent genome-wide asso-
ciation studies identified 16 independent risk loci for
development of BO (and/or OAC). The risk locus with the
strongest association was found within the CFTR gene.2 Inter-
estingly, there is an inverse relationship between Helicobacter
pylori infection and risk of BO. Helicobacter pylori may lower
acid production in the stomach by causing gastric inflammation
and atrophy of the acid-producing parietal cells, hence dimin-
ishing the frequency of GORD and consequently BO. Table 1
summarizes the risk factors for BO.Diagnosis
Endoscopy, typically via the trans-oral route, is the preferred
method for diagnosing BO. Accurate assessment can be
hampered by excessive motility of the gastrointestinal tract
during endoscopy and the common coexistence of a hiatus her-
nia, which can confound precise localization of the GOJ.
Endoscopic measurement of the BO segment has been
standardized using the Prague classification, which involves
documenting the maximum circumferential extension of the
columnar epithelium from the GOJ in centimetres (C score)
and the maximal total extension of the segment from the GOJ
(M score) (Figure 2). A major benefit of this standardized
nomenclature lies in communicating the endoscopic findings
between clinicians, particularly when treatment is envisaged.
The area of metaplasia should be systematically biopsied using
the Seattle protocol. This involves quadrantic biopsies taken
every 2 cm along the length of the metaplastic epithelium
(Figure 2), starting distally to prevent bleeding obscuring theMEDICINE xxx:xxx 2
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nosis and subsequent surveillance.
Histologically, there are three types of columnar metaplasia:
gastric, which contains mucus-secreting parietal and chief cells;
cardiac (transitional), composed almost entirely of mucus-
secreting cells; and intestinal, defined by the presence of goblet
cells. The latter, also termed intestinal metaplasia (IM), is more
likely to progress to OAC. American guidelines require the
presence of goblet cells for a diagnosis of BO, but this differs in
the UK because of concern that random sampling might miss the
presence of the goblet cells. However, in order to distinguish
between low and high risk of progression the UK surveillance
protocol varies according to the length of the segment and
whether or not IM is present.Screening and diagnostic referral pathways for
Barrett’s oesophagus
Screening interventions for BO seem appealing because >80%
patients with this condition are not diagnosed. However, the
overall low prevalence of OAC does not justify a population-
based endoscopic screening programme. Currently the British
Society of Gastroenterology guidelines suggest that screening can
be considered in patients with chronic GORD symptoms and
multiple risk factors (at least three of age 50 years or older, white
race, male sex and obesity). This threshold should be lowered for
patients who have a first-degree relative with BO or OAC.
Although high-definition white light endoscopy remains the gold
standard in diagnosing BO, new technologies to improve the
accuracy, feasibility and cost-effectiveness of screening are being
widely investigated.
Ultrathin transnasal endoscopy is more cost-effective than
traditional endoscopy as it does not require sedation. The scope
has a diameter of <6 mm and has been shown to have a similar
technical success rate to standard endoscopy, with higher
acceptability and preference for patients. It could be performed in
primary care, although the equipment is expensive and a skilled
operator is still required. In addition, the biopsies are very small
compared with standard endoscopy, which could compromise
the histopathological review. While suitable for diagnosis,
transnasal endoscopy is therefore not recommended for
surveillance. 2019 Published by Elsevier Ltd.
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measure the length of the BO and the Seattle biopsy protocol 
for diagnosis and surveillance of BO
Figure 2
MOUTH AND OESOPHAGUSNon-endoscopic tools which could be readily performed in
primary care are ideal for screening and there are promising data
on the Cytosponge-TFF3 test. The Cytosponge comprises a
small capsule tethered to a string. The capsule is swallowed in a
sitting position, its coating disintegrating on reaching the stom-
ach. This reveals a 3 cm diameter spherical sponge, which is then
withdrawn by pulling the string. On withdrawal, the device
samples the entire oesophageal lining. The collected cells can be
analysed for BO using the immunohistochemical biomarker
trefoil factor 3 (TFF3, a marker of columnar epithelium), and for
features suggestive of dysplasia (using other biomarker assays,
including TP53). Cytosponge sampling has been proven to be a
safe procedure with high acceptability ratings in several trials
and a large-scale randomized trial is underway. Similar non-
endoscopic approaches coupled with methylation markers are
also being investigated.Surveillance and dysplasia diagnosis
Routine surveillance for patients with BO remains controversial
due to the high cost and low cancer conversion rate. The ratio-
nale for repeated endoscopic monitoring is to allow for early, pre-
symptomatic detection of dysplasia or cancer at a point when
treatment can be preventive or curative. Several population-
based studies suggest that it results in earlier detection of can-
cer and may provide a survival benefit although lead time bias
may confound the results.3,4 Randomized controlled trials
(RCTs) analysing the effect of surveillance compared with
symptomatic referral in BO patients are underway (e.g. the BOSS
trial).
The British guidelines currently recommend surveillance with
regular endoscopic monitoring and histopathological assessment
with a tailored approach based on clinical and pathologicalMEDICINE xxx:xxx 3
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10.1016/j.mpmed.2019.02.005features.1 Short lengths (<3 cm) of BO that do not contain IM
have a particularly low risk of progression to dysplasia or cancer
(0.05%/year); hence the algorithm is adjusted according to the
presence of IM or dysplasia and the segment length (Figure 3).
Dysplasia is a histopathological diagnosis in which the
epithelial cells lose their polarity and develop nuclear crowding,
with increasingly elongated and hyperchromatic nuclei. Endo-
scopic detection of dysplasia, particularly LGD, can be chal-
lenging because the affected epithelium is often flat and
indistinct. The histological differentiation between degrees of
dysplasia (LGD versus HGD) can also be difficult, with significant
inter-observer variability. Therefore these samples should be
reviewed by two specialist pathologists, discussed at a specialist
multidisciplinary team (SMDT) meeting and reported using the
Revised Vienna Classification (2000) (Table 2). It is hoped that
molecular features can help to provide a more objective measure
of the propensity for malignancy, and p53 immunostaining is
currently recommended as an adjunct to histopathological diag-
nosis of dysplasia.
BO with changes classified as indefinite for dysplasia consti-
tutes a separate histological category, relating to atypical cyto-
logical changes considered too severe to be termed negative for
dysplasia but falling short of the criteria for true dysplasia. Care
should be used when interpreting this finding because underly-
ing LGD or HGD could be obscured by inflammation. These pa-
tients should be treated with optimal anti-reflux therapy and re-
scoped after 6 months and managed accordingly.
The development of advanced endoscopic techniques has
raised questions over which method is best for identifying
dysplasia. Regular surveillance with high-resolution endoscopy
and careful examination of the mucosal surface is the current
standard of care. Data demonstrate that there is a direct 2019 Published by Elsevier Ltd.
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Figure 3
MOUTH AND OESOPHAGUScorrelation between the time spent on inspecting the BO segment
and detection of HGD/OAC. Other methods have been advocated
to help localize areas of dysplasia that are not easily visible.
Standard chromoendoscopy agents, such as methylene blue,
acetic acid and indigo carmine, have previously been used, with
inconsistent results, and imaging technology is advancing which
negates the need for topical dyes.
Narrow-band imaging (NBI) is an example of virtual chro-
moendoscopy, one of the most widely studied tools for detecting
and characterizing early neoplasia in BO. NBI enhances light of a
short wavelength (blue and green in the visible spectrum) that
penetrates only superficially into the mucosa. This improves
imaging of the mucosal surface and related vascular pattern. A
simple validated system to identify dysplasia and OAC within BO
segments using NBI has recently been developed (the BING
criteria). This is based on a simple evaluation of the BO surface
and vascular patterns (regular versus irregular). In a recent
study, the BING criteria had an overall accuracy of 85% in
identifying patients with dysplasia. Moreover, NBI can be com-
bined with magnifying systems to improve the detailed charac-
terization of the vascular microarchitecture and glandular pit
pattern.
Autofluorescence imaging, which relies on endogenous fluo-
rophores being excited by short-wavelength light has a high rateVienna histological classification
Category Classification
1 Negative for dysplasia




5 Submucosal invasion by adenocarcinoma
Table 2
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scopy provides cellular resolution but is limited by a narrow field
of view and difficulties with image interpretation. An ideal
endoscopic tool should be able to rapidly examine the entire BO
segment and provide an accurate, automated analysis to localize
areas of concern for biopsy and treatment. This remains an area
of active investigation. Examples of advanced imaging tech-
niques are presented in Figure 4.Treatment of Barrett’s oesophagus and management
of dysplasia
Most patients with BO have reflux symptoms and should be
given long-term acid suppression treatment. Proton pump in-
hibitors (PPIs) have the best clinical profile for symptomatic
management. PPIs irreversibly block the Hþ/Kþ-ATPase pump in
acid-secreting gastric parietal cells. The addition of an H2-re-
ceptor antagonist to a PPI can help with nocturnal symptoms. If
inflammation is present during the endoscopic assessment of BO,
medication should be introduced or the dose of existing medicine
increased. This approach allows accurate histopathological
assessment of the degree of dysplasia in repeated endoscopy.
Anti-reflux surgery, usually laparoscopic Nissen fundoplication,
should be considered for patients who have persistent reflux
symptoms (confirmed by pH-monitoring) or are unable to take
PPIs without significant adverse effects.
As with the regular use of aspirin and non-steroidal anti-in-
flammatory drugs, it is currently debated whether PPIs should be
offered to all BO patients as a chemopreventive agent, irre-
spective of the presence of symptoms. PPIs effectively reduce
acid reflux, which is the main driver of BO, and downregulate
cyclooxygenase-2 expression, which might protect against
neoplastic progression. Most recently, the AspECT RCT
compared outcomes in BO patients treated with low- or high-
dose PPI (esomeprazole 20 mg or 40 mg twice daily), with or
without aspirin (300 mg/day). The study showed that high-dose
PPI slightly reduced all-cause mortality and incidence for HGD/ 2019 Published by Elsevier Ltd.
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Figure 4 Advanced endoscopic imaging techniques to identify dysplasia in BO. (a, b) 2.5% Acetic acid staining in a long segment of BO. Arrows
indicate an area of HGD, characterized by earlier loss of acetowhitening compared with the surrounding Barrett’s mucosa. (c, d) NBI. Arrows
indicate a slightly raised area of early adenocarcinoma with irregular vessels. (e, f) Autofluorescense imaging. Arrows indicate an area of early
adenocarcinoma characterized by abnormal autofluorescense signal (dark red compared with bright green).
MOUTH AND OESOPHAGUSOAC compared with low-dose PPI after a follow-up time of nearly
9 years ( p ¼ 0.038). Interestingly, aspirin alone did not provide
significant benefit, but a combination of high-dose PPI and
aspirin had a trend towards a stronger effect.
All patients with confirmed LGD (in two subsequent exami-
nations confirmed by pathologists) and HGD should be discussed
at an SMDT meeting and undergo high-resolution endoscopy at a
tertiary centre. Endoscopic abnormalities should be documented
using the Paris classification, which assesses the likelihood of a
lesion harbouring invasive disease. Endoscopic treatment is the
current gold standard in management of dysplasia. With LGD or
HGD without visible abnormality, endoscopic ablation is rec-
ommended, using argon plasma coagulation (APC) and, moreMEDICINE xxx:xxx 5
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10.1016/j.mpmed.2019.02.005recently, radiofrequency ablation (RFA). The aim of such treat-
ment is to ablate (burn) the metaplastic mucosa and allow re-
epithelialization with squamous epithelium and usually in-
volves several sessions.
The efficacy of APC in BO treatment has been demonstrated in
numerous case-series reports; most recently, in a pilot RCT, it
was found to be similarly effective to RFA in terms of BO erad-
ication after endoscopic mucosal resection (EMR). Overall, APC
is cheaper and more widely available than RFA; however, it is
less standardized and more often associated with the presence of
post-treatment ‘buried glands’, defined as the presence of resid-
ual Barrett’s epithelium under the neo-squamous epithelium.
APC has recently been combined with submucosal sodium 2019 Published by Elsevier Ltd.
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MOUTH AND OESOPHAGUSchloride injection (hybrid-APC) to improve its safety compared
with conventional APC.
In many countries, RFA has become the method of choice to
treat dysplastic BO. Two basic types of RFA are available e RFA
360 and RFA 90. In RFA 360, a balloon with electrodes is
insufflated within the oesophageal lumen to deliver a shallow
circumferential burn to the luminal surface. RFA 90 is used to
focally burn small areas of Barrett’s epithelium (Figure 5). The
initial multicentre, sham-controlled trial showed complete erad-
ication of IM in 77.4% in patients with dysplastic BO treated with
RFA; this resulted in lower disease progression rates (3.6%
versus 16.3%, p ¼ 0.03) and fewer cancers (1.2% versus. 9.3%,
p ¼ 0.045) compared with the control group (sham procedure). A
more recent RCT of 68 patients with LGD treated with RFA and
an equal number of patients undergoing annual endoscopic
surveillance showed that, over 3 years’ follow-up, only 1% of
patients in the treatment arm progressed to HGD or OAC,
compared with 26.5% in the control arm (p < 0.001). Complete
eradication of dysplasia and IM by RFA was achieved in 98% and
90% of cases, respectively. The most common complication was
a stricture, which occurred in 12% of patients, but this was
successfully resolved by endoscopic dilation in all cases. Of note,
endoscopic monitoring is still recommended after ablative ther-
apy because there is a significant risk of recurrence in these
patients.
For dysplasia or early cancer within a visible lesion, endo-
scopic resection should be performed, with either EMR or
endoscopic submucosal dissection (ESD). Band-ligation EMR is
the most common technique used in the setting of BO. In this, a
transparent suction cap with rubber bands is fitted to the tip ofFigure 5 RFA treatment for BO with dysplasia. (a, b) RFA 360 balloon to tre
residual BO.
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the cap, and a ligation band is then deployed. This creates a
pseudopolyp that is then resected beneath the band by a metal
polypectomy snare (Figure 6). EMR has a favourable safety
profile. In large database studies, the rate of acute complications,
such as bleeding and perforations, were 1.2e1.8% and 0e2.4%,
respectively. More common were the late complications such as
strictures, in 1.0% up to 49.7% of EMRs involving a large,
circumferential resection. All strictures were, however, success-
fully treated with endoscopic dilation.
EMR provides histological information including prognostic
features such as degree of cancer differentiation, presence or
absence of lymphovascular invasion, depth of cancer invasion
and distance of cancer from the deep and lateral resection mar-
gins. These criteria aid in determining the suitability of curative
endoscopic therapy. Lesions confined to the mucosa have a very
low rate of lymphatic involvement, so EMR is considered cura-
tive for adenocarcinoma limited to the mucosal layer (T1a) in
conjunction with low or moderate differentiation of cancer, no
lymphovascular invasion and clear resection margins. EMR is
frequently performed piecemeal, and histological complete
resection (R0) is difficult to assess in such cases as this requires a
tumour to be included in only one specimen.
ESD is a demanding procedure which has the advantage over
EMR of allowing en bloc resection of larger neoplastic lesions.
The procedure is initiated by injection of fluid (typically sodium
chloride with epinephrine, and indigo carmine dye) underneath
the target lesion; this is followed by circumferential cutting,
dissection of the submucosal layer, coagulation of visible vessels
and removal of the whole specimen. A recent RCT comparingat a circumferential segment of BO. (c, d) RFA 90 to treat small areas of
 2019 Published by Elsevier Ltd.
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Figure 6 EMR for early adenocarcinoma in BO. (a) Nodular lesion corresponding to early adenocarcinoma. (b) Marking the lesion before resection.
(c) A transparent suction cap is fitted to the tip of the endoscope, the targeted tissue is sucked inside, and a ligation band is then deployed,
creating a pseudopolyp. (d) Resection with a metal polypectomy snare.
MOUTH AND OESOPHAGUSEMR with ESD in the treatment of BO-related neoplasia showed
that both methods were comparably effective in terms of the
need for surgery, neoplasia remission and recurrence. ESD was,
however, more time-consuming and led to more severe adverse
events. Overall, ESD has not been shown to be superior to EMR,
although it can be considered in selected cases, such as larger
lesions (>15 mm in size), poorly lifting lesions and lesions at
increased risk of submucosal invasion.
For adenocarcinoma with superficial submucosal invasion
(T1b sm1), data are conflicting regarding the risk of lymph node
involvement. A growing body of evidence shows that this risk is
lower than previously reported, and some guidelines consider
endoscopic therapy as an alternative to oesophagectomy in cases
of low-risk T1b adenocarcinoma; this is defined as cancer limited
to the superficial layer (500 micrometres) of the submucosa
(Sm1) that is well differentiated, has clear resection margins and
shows no lymphovascular invasion. This approach is especially
recommended for poor surgical candidates. Such therapeutic
decisions should be always made by a multidisciplinary team.
After endoscopic resection for focal dysplasia, patients should be
offered subsequent ablative therapy for the residual BO segment.
Oesophageal adenocarcinomaEpidemiology
In the UK, the overall annual incidence of oesophageal cancer
(14.1 per 100,000 population in 2015) is similar to the annual
mortality because of the associated poor 5-year survival ofMEDICINE xxx:xxx 7
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death, accounting for 5% of all cancer deaths in 2016. Although
squamous cell carcinoma of the oesophagus remains the domi-
nant subtype of oesophageal cancer worldwide, the incidence of
OAC, particularly in men, has been rapidly increasing in the
Western world. Adenocarcinoma currently accounts for more
than half of oesophageal cancers in England. The high mortality
stems from the appearance of symptoms late in the disease when
spread has already occurred beyond the primary site. Adeno-
carcinomas occurring within 5 cm of the junction are termed GOJ
cancers. These are currently subdivided using the Siewert clas-
sification (Figure 7), based on whether the bulk of cancer lies in
the stomach or the oesophagus. The precision and usefulness of
this classification are, however, under debate.Diagnosis
Most patients with oesophageal cancer present with difficulty
swallowing (dysphagia) or pain when swallowing (odynopha-
gia). This starts with solid foods (e.g. bread, meat) and pro-
gresses until even liquids are difficult to swallow. In 2005, the
National Institute for Health and Care Excellence issued guide-
lines indicating that patients of any age with dyspepsia and
progressive dysphagia should have an urgent referral for
endoscopy to exclude malignancy.
Dysphagia is associated with weight loss, anaemia and/or
symptoms from metastatic disease. The oesophagus can distend
to a remarkable degree before swallowing difficulties are noticed,
and this contributes to the late diagnosis. Some patients present 2019 Published by Elsevier Ltd.
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MOUTH AND OESOPHAGUSwith haematemesis (vomiting blood) and melaena (dark
appearance of stools from the presence of digested blood). Fa-
tigue can occur as a consequence of anaemia related to chronic
occult bleeding from a tumour. Endoscopy with biopsies remains
the gold standard in the diagnosis of OAC. Typically, a set of at
least six biopsies should be taken from suspicious lesions to
provide adequate tissue material for histopathological assess-
ment. Histology should be reported in accordance with the World
Health Organization classification and include information on
subtype of cancer and grade.Staging of oesophageal cancer
Once oesophageal cancer has been diagnosed, it is staged ac-
cording to the tumour, node, metastasis (TNM) classification
(8th edition; Figure 8). Most people who present with ‘alarm’
symptoms, such as dysphagia, already have locally advanced
disease (T3) and lymph node involvement (N1). T1 lesions are
determined most accurately by histological examination, ob-
tained by EMR or ESD. The lesion should ideally be removed en
bloc so the pathologist can accurately determine the depth of
cancer penetration. Radiological investigations are useful for
staging more advanced cancers to determine lymph node
involvement and metastases. Recent attempts have been made to
identify prognostic molecular biomarkers, but further work is
required before this can be incorporated into routine practice in
the way it is for breast cancer.
Computed tomography (CT) is very useful for staging nodes
(N) and metastases (M) but has poor sensitivity in differentiating
between the T stages (often understaging the tumour), particu-
larly when there is no mediastinal invasion. To obtain the best
views, CT should be performed after the stomach has been dis-
tended with water. The most common sites for metastases are the
liver, lungs, adrenal glands and peritoneum. Magnetic resonance
scanning has not been shown to have any additional benefit.MEDICINE xxx:xxx 8
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detect the synthetic glucose analogue 2-fluoro-2-deoxyglucose,
which contains the radioisotope 18F and is incorporated into
tissue with a high rate of glycolysis. PET is useful for detecting
distant lymph node involvement and metastases in patients
being considered for surgery and is particularly useful in clari-
fying the involvement of nodes that were classified as indeter-
minate on CT by size. This is now most commonly performed in
combination with a co-registered CT (CT-PET) to enable accurate
localization of areas of high signal. It can also be used as a tool
for monitoring the response to chemotherapy.
Endoscopic ultrasound (EUS) is more accurate than CT in
discerning the degree of invasion through the layers of the
oesophagus, as well as determining the size and malignant
characteristics of local lymph nodes. However, it is currently
poor for distinguishing between the T1 stages (T1a versus T1b).
It also allows for EUS-guided fine needle aspiration of suspicious
lymph nodes, but this may not be possible when the cancer has
caused stricturing of the oesophagus.
Laparoscopy allows the detection of low-volume hepatic or
peritoneal metastases or seeding that would not normally be
detected on CT and is a useful aid in assessing tumour opera-
bility. This is particularly helpful for tumours of the GOJ or with
gastric involvement.
Other ‘staging adjuncts’ should be used to address specific
clinical queries. These include endobronchial ultrasound, which
can detect airway infiltration in tumours of the upper oesoph-
agus. It may also be useful for sampling mediastinal lymph nodes
that are not accessible by EUS, especially in the paratracheal
space. Thoracoscopy can also be required in specific
circumstances.Management of oesophageal cancer
Oesophageal cancer in the UK is now managed in regional
specialist centres by an SMDT. This team should include sur-
geons, radiation and medical oncologists, endoscopists, nutri-
tionists, radiologists, pathologists, palliative care physicians,
specialist nurses and individuals with knowledge of clinical
trials.
Endoscopic therapy: as mentioned earlier, endoscopic resec-
tion should be used to resect focal lesions, usually within an
area of BO; this can be sufficient if the cancer is intramucosal
or, in some circumstances, is penetrating only the superficial
layers of the submucosa (T1b). The data show that patients
with early oesophageal cancer managed with endoscopic
therapy have comparable long-term survival to those treated
with surgical resection.
Endoscopic therapy also has a role in palliative treatment
and can be used to manage dysphagia, bleeding or fistula
formation in more advanced cancers. Stents provide good
palliation for patients with malignant tracheo-oesophageal
fistulae. However, they cannot be used if a tumour extends
to within 2 cm of cricopharyngeus, and tend not to function as
well at the GOJ. Currently, self-expanding covered stents are
being more commonly used, reducing the need for oesophageal
dilatation before their placement and decreasing tumour
overgrowth through the stent. Tumours can be downsized with
techniques such as laser photocoagulation, local diathermy and 2019 Published by Elsevier Ltd.




T (primary tumour) stage
Stage Extent of maximal penetration to the cancer
Tx Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ/high-grade dysplasia
T1a Tumour invades lamina propria or muscularis mucosae
T1b Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades adventitia
T4a Tumour invades pleura, pericardium azygos vein, diaphragm, 
 or peritoneum
T4b Tumour invades other adjacent structures such as aorta, vertebral 
 body or trachea
N (regional lymph node) stage
Nx Regional lymph node cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1–2 regional lymph nodes
N2 Metastasis in 3–6 regional lymph nodes
N3 Metastasis in >7 regional lymph nodes
M (distant metastasis) stage
M0 No distant metastasis
M1 Distant metastasis present







The TNM classification (8th edition) of malignant oesophageal tumours
Figure 8
MOUTH AND OESOPHAGUSsclerotherapy (with alcohol), or with brachytherapy (internally
delivered radiotherapy); however, the requirement for repeat
procedures and the lack of effect on overall survival make
these techniques of limited usefulness. The patient’s overall
fitness and risk of aspiration pneumonia, oesophageal perfo-
ration, bleeding or formation of tracheo-oesophageal fistulae
must be considered when undertaking any of these procedures.
Surgery: this is generally undertaken only with the intent to
cure, but even then median survival is only up to 46 months in
tertiary care centres. For early oesophageal cancer (T1) after
EMR or ESD staging, surgery should be reserved for cases with
high risk of lymph node metastasis, as previously discussed.
Surgery is generally combined with neoadjuvant oncological
therapy, but for selected patients with T1 and T2 disease with
low-risk features (size <2 cm and well-differentiation), surgery
alone can be sufficient. The morbidity and mortality associated
with oesophagectomy are improving, especially for early cancers,
for which there are now minimally invasive laparoscopic and/or
thoracoscopically assisted approaches.MEDICINE xxx:xxx 9
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10.1016/j.mpmed.2019.02.005The operative approach depends on the precise site of the
lesion and the need for lymph node resection. Options include
the following:
 Two-phase Ivor Lewis oesophagectomy e the most
widely practised operation, this entails a laparotomy fol-
lowed by a right thoracic approach with an anastomosis
high in the chest, and allows a thorough
lymphadenectomy.
 Laparoscopically assisted oesophagectomy or minimally
invasive oesophagectomy e this permits lymph node
resection and has the advantage of reduced recovery times.
However, the technique is used primarily for early disease
because of concerns about achieving adequate lymph node
clearance.
 Trans-hiatal oesophagectomy e this entails the formation
of a high anastomosis in the neck without thoracotomy. A
less radical lymph node dissection restricts this approach
to early disease.
 Merendino procedure e a more limited resection with a
jejunal interposition is used for early disease because it has 2019 Published by Elsevier Ltd.
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MOUTH AND OESOPHAGUSlower morbidity and mortality rates, and gives a good
functional result.
Whichever approach is used, the most important objective is
to achieve a clear resection margin. A recent meta-analysis has
shown that patients with involved margins have a significantly
poorer prognosis. Various neoadjuvant treatments are available
to help downsize these tumours and aid complete resection.
Chemotherapy: this is used in different contexts in the man-
agement of OAC. For patients with operable disease, neoadjuvant
or perioperative chemotherapy is used to improve overall sur-
vival. The Medical Research Council (MRC) OEO2 trial was the
first study to demonstrate that chemotherapy in the form of
cisplatin and 5-fluorouracil (5-FU) before oesophagectomy
improved 5-year overall survival from 17.1% to 23.0%. The
survival benefit was similar for oesophageal squamous cancer
and adenocarcinoma.
The subsequent MRC ST02 (MAGIC) trial examined the use of
the three-drug combination epirubicin, cisplatin and 5-FU (ECF)
given before and after surgery. The trial studied gastric cancers,
but the cohort contained many patients with lower oesophagus
and GOJ tumours. This study demonstrated an increased 5-year
overall survival of 36% for the ECF group, compared with the
surgery group (23%; p ¼ 0.009). 5-FU can be replaced by cape-
citabine e an oral form of the drug that has been shown to have
equivalent efficacy and is often used as an alternative to infu-
sional 5-FU for patient convenience (giving the chemotherapy
regimen ECX). An improved pathological response, compared
with ECF, was recently shown in patients treated with a
docetaxel-based triplet chemotherapy (FLOT regimen e doce-
taxel, oxaliplatin, 5-FU) before surgical resection.
Chemotherapy is also used in patients with metastatic inop-
erable disease to improve quality of life and prolong survival.
Similar drugs are used in the perioperative setting. The REAL 2
study suggests there might be a small advantage of replacing
cisplatin with another member of the platinum family, oxalipla-
tin. EOX (epirubicin, oxaliplatin, capecitabine) is a common
regimen for patients with metastatic disease. There is evidence
for the use of other drugs (e.g. docetaxel) in the second-line
setting, but patients should be carefully assessed and involved
in discussions about treatment selection as the goal of therapy in
this context is to maximize quality of life.
As the molecular profile of OAC is being characterized
through genome-wide sequencing efforts and systematic
assessment of receptor tyrosine kinase expression, it is
becoming more feasible to introduce molecular targeted ther-
apy in curative as well as advanced disease settings. However,
a personalized approach seems necessary because of hetero-
geneity of the somatic alterations. Overexpression of human
epidermal growth factor receptor 2 (HER2) is common in
junctional and oesophageal adenocarcinomas (32.2% in the
ToGA study cohort and 30% in the TCGA cohort). This over-
expression was first noted in breast cancer, and the targeted
monoclonal antibody trastuzumab has been used to improve
survival dramatically in these patients. The ToGA trial found
that trastuzumab prolonged survival in HER2-overexpressing
inoperable gastric and GOJ tumours. New agents including
lapatinib, a dual epidermal growth factor receptor and HER2
tyrosine kinase inhibitor, and pertuzumab, another anti-HER2MEDICINE xxx:xxx 10
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other cancers (e.g. HER2-expressing breast cancer), are being
examined in this patient cohort.
Tumours can only grow through recruitment of a blood sup-
ply and angiogenesis; hence the tumour vasculature, which is
thought to have greater genomic stability and lead to a more
predictable response, is also a molecular target. Ramucirumab, a
monoclonal antibody against the vascular endothelial growth
factor receptor (VEGFR) 2, given both as a single agent and in
conjunction with paclitaxel, was shown to increase overall sur-
vival in patients with gastric and GOJ adenocarcinomas. Because
recent molecular studies suggest that OACs resemble chromo-
somally unstable gastric cancers, these therapies also seem
justified for OACs.
Patients with advanced metastatic disease need good pallia-
tive care to manage symptoms such as pain and address any
psychological concerns. Evidence from studies in patients with
tumours at other sites suggests that early palliative care can be as
effective as chemotherapy in improving quality of life.
Radiotherapy: definitive treatment of oesophageal tumours with
chemo-radiotherapy alone is limited to more radio-sensitive
squamous cell cancers. However, it can be an option for pa-
tients with OAC who are unsuitable for surgical treatment or
decline such treatment. Chemo-radiation has been used in the
neoadjuvant context for the management of oesophageal cancer,
and the CROSS trial has demonstrated this to be superior to
surgery alone. These results, however, were predominantly
driven by squamous cell carcinoma and were only marginally
significant for adenocarcinomas. An ongoing trial comparing
neoadjuvant chemotherapy and neoadjuvant chemo-
radiotherapy in oesophageal and GOJ adenocarcinomas (Neo-
AEGIS trial) should provide more evidence on the role of neo-
adjuvant chemo-radiation in OAC treatment.
Chemo-radiotherapy entails the use of cisplatin and 5-FU,
alongside external-beam radiotherapy to a dose of 45 Gy in 25
fractions over a period of 5 weeks. In the UK, this intensive
treatment is currently reserved for relatively fit patients with a
good performance status. The optimal concurrent chemotherapy
is being examined in the current NeoSCOPE trial of neoadjuvant
chemo-radiotherapy in the UK. External-beam radiotherapy can
also be used in the palliation of symptoms including dysphagia,
bleeding and pain from bone metastases, and in the treatment of
brain metastases. AKEY REFERENCES
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Rev Dis Prim 2017; 3: 17048.TEST YOURSELFTo test your knowledge based on the article you have just read, please complete the questions below. The answers can be found at the
end of the issue or online here.Question 1
A 46-year-old man presented after undergoing endoscopy as part
of routine surveillance of his short segment Barrett’s oesophagus
(C2M2 according to the Prague classification).
Investigation
 Biopsies taken according to the Seattle protocol showed
intestinal metaplasia without dysplasiaWhat is the next most appropriate step?
A. Reassure and discharge the patient
B. Keep him under surveillance with repeat endoscopies every
3e5 years
C. Perform endoscopic ablation treatment
D. Refer for multidisciplinary team meeting review
E. Repeat the endoscopy with fluorescein guidanceQuestion 2
A 56-year-old man presented for review after urgent endoscopy
for mild dysphagia and upper abdominal pain. Endoscopy had
identified a flat long segment of Barrett’s oesophagus (C4M5
according to the Prague classification) with several erosions
corresponding to grade B oesophagitis according to the Los
Angeles classification.
Investigation
 Biopsies showed intestinal metaplasia with features in-
definite for dysplasiaWhat is the most appropriate next step in his management?
A. Repeat endoscopy in 2e3 years
B. Repeat endoscopy in 1 year
C. High-dose proton pump inhibitor treatment, with no need
for repeat endoscopy
D. High-dose proton pump inhibitor treatment and repeat
endoscopy in 6 months
E. Referral for radiofrequency ablation treatmentQuestion 3
A 78-year-old woman presented for review after endoscopy for a
long history of substernal pain and reflux. Endoscopy had shown
a short segment of Barrett’s oesophagus (C1M2 according to the
Prague classification) with an 8 mm nodule. She was moderately
fit (World Health Organization performance status 2), but had
type 2 diabetes mellitus treated with insulin, essential hyper-
tension and chronic obstructive pulmonary disease.
Investigation
 Biopsies taken from the lesion showed moderately differ-
entiated adenocarcinomaWhat is the most appropriate next step in management to
consider in the multidisciplinary team meeting?
A. Long-term proton pump inhibitors
B. Radiofrequency ablation treatment
C. Endoscopic mucosal resection
D. Oesophagectomy
E. Radio/chemotherapy 2019 Published by Elsevier Ltd.
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